Patient Safety

DisposeRx Launches Medication Stewardship Series on Unsafe Drug Disposal

DisposeRx Launches Medication Stewardship Series on Unsafe Drug Disposal

Southern Pines, N.C. – September 16, 2026 -- DisposeRx, Inc. has launched a new monthly editorial series, the DisposeRx Medication Stewardship Center, aimed at reshaping how healthcare providers, pharmacists and caregivers manage the end stage of a prescription's life cycle.

DisposeRx CEO frames disposal as a patient safety issue, not just an environmental one

"This is not simply a conversation about medication disposal. It is a conversation about Medication Safety and completing the prescription journey," said William Simpson, CEO of DisposeRx. He said the starting point for the discussion is the household medicine cabinet, where unused prescriptions commonly accumulate.

Fibryga Cuts Blood Transfusions 19% in Cardiac Surgery Subgroups

Fibryga Cuts Blood Transfusions 19% in Cardiac Surgery Subgroups

Paramus, N.J. – – September 15, 2026 -- A prespecified secondary analysis of the landmark FIBRES trial found that Octapharma's fibryga (fibrinogen [human]) cut 24-hour allogeneic blood-product transfusion requirements by 19% versus cryoprecipitate in two overlapping patient subgroups, according to findings published in the Journal of Cardiothoracic and Vascular Anesthesia.

Non-critical and elective surgery patients showed the sharpest transfusion reductions

Among 634 patients classified as non-critical before surgery -- 86% of the primary trial population -- those receiving fibryga required 13.6 blood-product units on average versus 16.2 units for cryoprecipitate recipients, a 19% relative reduction. In the 466-patient elective-surgery subgroup, representing 63% of the primary population, fibryga patients received 11.7 units compared with 14.4 units for cryoprecipitate, matching the 19% relative reduction.